Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases

scientific article published on 11 January 2018

Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.NMD.2018.01.003
P698PubMed publication ID29433793

P50authorIvon CuscóQ34448131
Sara BernalQ73617080
P2093author name stringPablo Fuentes-Prior
Salud Borrego
Concepción Hernández-Chico
José M Millán
Raquel M Fernández
Francesca March
Adoración Venceslá
Eduardo F Tizzano
Laura Alías
Elena Aller
Maite Calucho
Francisco J Rodríguez-Álvarez
P433issue3
P304page(s)208-215
P577publication date2018-01-11
P1433published inNeuromuscular DisordersQ1981326
P1476titleCorrelation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases
P478volume28

Reverse relations

cites work (P2860)
Q55339830Accurate diagnosis of spinal muscular atrophy and 22q11.2 deletion syndrome using limited deoxynucleotide triphosphates and high-resolution melting.
Q89641284Analysis of FUS, PFN2, TDP-43, and PLS3 as potential disease severity modifiers in spinal muscular atrophy
Q93088149Biomarkers and the Development of a Personalized Medicine Approach in Spinal Muscular Atrophy
Q100504061CMAP changes upon symptom onset and during treatment in spinal muscular atrophy patients: lessons learned from newborn screening
Q91784761Complete sequencing of the SMN2 gene in SMA patients detects SMN gene deletion junctions and variants in SMN2 that modify the SMA phenotype
Q52804349Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany.
Q92297063High-throughput genetic newborn screening for spinal muscular atrophy by rapid nucleic acid extraction from dried blood spots and 384-well qPCR
Q90124758Infants Diagnosed with Spinal Muscular Atrophy and 4 SMN2 Copies through Newborn Screening - Opportunity or Burden?
Q99585557Intragenic and structural variation in the SMN locus and clinical variability in spinal muscular atrophy
Q104567667Molecular diagnosis and genetic counseling for spinal muscular atrophy (SMA)
Q98945157NGS-based spinal muscular atrophy carrier screening of 10,585 diverse couples in China: a pan-ethnic study
Q64276902Neurofilament as a potential biomarker for spinal muscular atrophy
Q58779205New Directions for SMA Therapy
Q92539534Newborn Screening for Spinal Muscular Atrophy in China Using DNA Mass Spectrometry
Q89595212Nusinersen treatment and cerebrospinal fluid neurofilaments: An explorative study on Spinal Muscular Atrophy type 3 patients
Q64075875Nusinersen: A Novel Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy
Q90593635One Year of Newborn Screening for SMA - Results of a German Pilot Project
Q104567661Pathogenesis and therapeutic targets in spinal muscular atrophy (SMA)
Q91752254Perspectives in genetic counseling for spinal muscular atrophy in the new therapeutic era: early pre-symptomatic intervention and test in minors
Q89626564RESTORE: A Prospective Multinational Registry of Patients with Genetically Confirmed Spinal Muscular Atrophy - Rationale and Study Design
Q100566572SMN1 copy-number and sequence variant analysis from next-generation sequencing data
Q100559905Spinal muscular atrophy - insights and challenges in the treatment era
Q92146942The frequency of SMN gene variants lacking exon 7 and 8 is highly population dependent
Q90679196The implementation of newborn screening for spinal muscular atrophy: the Australian experience
Q89109004Utility of two SMN1 variants to improve spinal muscular atrophy carrier diagnosis and genetic counselling

Search more.